Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 17 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the continued development of the Company's pipeline.

Up to 57,600 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee's continued service relationship with UroGen.

The RSUs are subject to the terms and conditions of UroGen's 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product Jelmyto® (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen Pharma Ltd.


These press releases may also interest you

at 03:30
Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687
Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced that the U.S. Food and Drug Administration (FDA) has...

at 03:30
42com Launches New ISP and LEO Satellite Infrastructure Services in Italy
42com, a global leader in the telecom industry, is proud to announce the expansion of its service offerings, through the acquisition of assets from Milano Teleport Srl. As a result, the company has now become an authorized internet service provider...

at 03:30
Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer
Curve Therapeutics ("Curve" or the "Company"), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging...

at 03:23
Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding
Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. and OSAKA University Venture Capital, with participation...

at 03:00
DevEx Connect Launches Series of U.K. Events to Elevate the Developer Experience and Support Software Communities
DevEx Connect, the global Developer Experience event series, today announced its first series of events to foster the growth and health of software communities. The first event will occur in Manchester at etc.venues on October 29. DevEx Connect...

at 03:00
Don't Get Hacked! Power Up Your Cyber Defenses with All Access This October
This October, sharpen your digital defenses and navigate the ever-evolving world of cybersecurity with All Access with Andy Garcia, the captivating public television program that delves into critical issues shaping our world. Throughout National...

More news about Science and technology...


News published on and distributed by: